Intestinal atresia
diseaseOn this page
Also known as atresia of the intestinecongenital intestinal atresiaintestinal atresia (disease)
Summary
Intestinal atresia (MONDO:0001045) is a disease and 7 clinical trials. Top therapeutic interventions include fish oil triglycerides and indocyanine green acid form. A subtype of intestinal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | intestinal atresia |
| Mondo ID | MONDO:0001045 |
| MeSH | D007409 |
| DOID | DOID:10486 |
| NCIT | C84790 |
| UMLS | C0021828 |
| MedGen | 7129 |
| Is cancer (heuristic) | no |
Also known as: atresia of the intestine · congenital intestinal atresia · intestinal atresia · intestinal atresia (disease)
Data availability: 1 HPO phenotype.
Disease family
This is a subtype of intestinal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › intestinal atresia
Related subtypes (57): steatorrhea, angiodysplasia of intestine, endometriosis of intestine, hypertrophic pyloric stenosis, mucocele of appendix, gastroenteritis, diverticulitis, intestinal obstruction, postgastrectomy syndrome, chronic intestinal vascular insufficiency, bowel dysfunction, irritable bowel syndrome, Whipple disease, inflammatory bowel disease, intestinal polyp, necrotizing enterocolitis, intestinal perforation, neurogenic bowel, pneumatosis cystoides intestinalis, volvulus of midgut, abetalipoproteinemia, aplasia cutis congenita-intestinal lymphangiectasia syndrome, trichohepatoenteric syndrome, protein-losing enteropathy, chronic diarrhea with villous atrophy, Satoyoshi syndrome, glucose-galactose malabsorption, congenital diarrhea 7 with exudative enteropathy, chronic atrial and intestinal dysrhythmia, congenital enterocyte heparan sulfate deficiency, short bowel syndrome, intractable diarrhea-choanal atresia-eye anomalies syndrome, solitary rectal ulcer syndrome, NK-cell enteropathy, chronic intestinal failure, intestinal lymphangiectasia, refractory celiac disease, eosinophilic gastrointestinal disease, cryptogenic multifocal ulcerous stenosing enteritis, chronic enteropathy associated with SLCO2A1 gene, cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder, malakoplakia, malabsorption syndrome, ischemic bowel disorder, intestinal neoplasm, intestinal motility disease, 4-hydroxyphenylacetic aciduria, parasitic intestinal disorder, Aeromonas hydrophila intestinal disease, large intestine disorder, small intestine disorder, primary desmosis coli, isolated mesenteric vein thrombosis, collagenous sprue, visceral leiomyopathy, African degenerative, intestinal dysmotility syndrome, intestinal fistula
Subtypes (2): duodenal atresia, multiple intestinal atresia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02370251 | PHASE2/PHASE3 | COMPLETED | Compassionate Use of Omegaven in Children |
| NCT07526636 | Not specified | NOT_YET_RECRUITING | Pattern And Outcome Of Neonatal Gastrointestinal Emergencies In Assiut University Children Hospital |
| NCT01062815 | Not specified | TERMINATED | Prevention of Parenteral Nutrition-Associated Cholestasis With Cyclic Parenteral Nutrition in Infants |
| NCT03666767 | Not specified | COMPLETED | Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries |
| NCT03754907 | Not specified | UNKNOWN | Stapled Anastomosis Versus Hand-sewn for Neonate With Intestinal Atresia |
| NCT04020939 | Not specified | COMPLETED | The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery. |
| NCT04431869 | Not specified | COMPLETED | In-Utero Vascular Accidents in Neonates From COVID-19 Infected Mothers |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FISH OIL TRIGLYCERIDES | 4 | 1 |
| INDOCYANINE GREEN ACID FORM | 4 | 1 |